CN113603694A - 1, 2-diketone compound and preparation method and application thereof - Google Patents
1, 2-diketone compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN113603694A CN113603694A CN202110806332.9A CN202110806332A CN113603694A CN 113603694 A CN113603694 A CN 113603694A CN 202110806332 A CN202110806332 A CN 202110806332A CN 113603694 A CN113603694 A CN 113603694A
- Authority
- CN
- China
- Prior art keywords
- formula
- preparation
- diketones
- compound shown
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1, 2-diketone compound and a preparation method and application thereof. The invention develops the aryl substituted imidazole compound with novel structure, the preparation method thereof and the application thereof in preparing anti-tumor drugs, and the process has mild reaction conditions, convenient operation, low cost and wide industrial application prospect, and the product purity reaches more than 97 percent. The aryl-substituted imidazole compound provided by the invention shows a certain antitumor activity, lays a foundation for screening and developing new drugs, and has a good practical value.
Description
(I) technical field
The invention relates to a 1, 2-diketone compound and a preparation method and application thereof.
(II) background of the invention
1, 2-diketone compounds are important organic synthesis intermediates which are widely applied to synthesis of pesticides, medicines and the like, and meanwhile, the compounds also have multiple biological activities, and are one of hot spots of research in recent years. The traditional 1, 2-diketone compound is mainly prepared by oxidation of alkyne, alkene or diol compounds, but has many defects to limit the application. Therefore, the preparation of the novel 1, 2-diketone compound has important theoretical significance and practical application value.
Disclosure of the invention
The invention aims to provide a 1, 2-diketone compound, a preparation method thereof and application thereof in preparing antitumor drugs
In order to achieve the purpose, the invention adopts the following technical scheme:
1, 2-diketones of formula (I):
in the formula (I), R1Or R2Each independently is C1～C10Alkyl, or R1、R2Are connected into a ring and are combined with N between the two to form C containing N or N, O4～C8The heterocyclic ring of (1); r3Is C4～C8Heteroaryl, phenyl or by C1～C10Alkyl radical, C1～C10Alkoxy or halogen substituted phenyl.
Further, said R1Or R2Each independently preferably being methyl, ethyl, or R1、R2Linked to form a ring and combined with the N between the two to form a pyrrolidine ring, a piperidine ring or a morpholine ring.
Further, said R3Preferably furyl, thienyl, phenyl or phenyl substituted by methyl, methoxy, fluoro, chloro or bromo.
Most preferably, the 1, 2-diketones of formula (I) are one of the following:
the invention provides a preparation method of a 1, 2-diketone compound shown in a formula (I), which comprises the following steps:
mixing a triazine compound shown in a formula (II) and a ketone compound shown in a formula (III), adding the mixture into a solvent, stirring and reacting for 5-20 hours at the temperature of 80-150 ℃ under an oxygen atmosphere, and after the reaction is finished, obtaining a reaction liquid and carrying out post-treatment to obtain a 1, 2-diketone compound shown in a formula (I); the mass ratio of the triazine compound shown in the formula (II) to the ketone compound shown in the formula (III) is 1: 2.4 to 3.0; the solvent is halogenated aromatic hydrocarbon or amide compounds;
r in formula (II) or formula (III)1、R2、R3Each as defined above.
Further, copper salt is added into the solvent before reaction, and the mass ratio of the triazine compound shown in the formula (II) to the copper salt is 1: 0 to 0.2(0 means infinitely close to 0 but not 0), and the amount of the copper salt is not 0.
Preferably, the copper salt is cuprous chloride, cuprous bromide, cupric chloride, cupric bromide or cupric acetate.
Still further, before the reaction, halogen is added into the solvent, and the mass ratio of the triazine compound shown in the formula (II) to the halogen is 1: 0 to 3.0(0 means infinitely close to 0 but not 0), and the amount of the halogen is not 0.
Preferably, the halogen is iodine.
Furthermore, an oxidant is added into the solvent before the reaction, and the quantity ratio of the triazine compound shown in the formula (II) to the halogen substance is 1: 0 to 1.4(0 means infinitely close to 0 but not 0), the amount of the substance of the oxidizing agent being not 0; the oxidant is m-chloroperoxybenzoic acid and K2S2O4Or bis-trifluoroacetyliodobenzene.
Preferably, the oxidizing agent is m-chloroperoxybenzoic acid.
Specifically, the invention provides a preparation method of the 1, 2-diketone compound shown in the formula (I), which specifically comprises the following steps:
mixing a triazine compound shown in a formula (II) and a ketone compound shown in a formula (III), adding the mixture into a solvent, stirring and reacting for 5-20 hours at the temperature of 80-150 ℃ under the action of copper salt, halogen and an oxidant under an oxygen atmosphere, and after the reaction is finished, obtaining a reaction liquid and carrying out post-treatment to obtain a 1, 2-diketone compound shown in a formula (I); the amount ratio of the triazine compound shown in the formula (II), the ketone compound shown in the formula (III), the copper salt, the halogen and the oxidant is 1: 2.4-3.0: 0-0.2: 0-3.0: 0 to 1.4; the solvent is halogenated aromatic hydrocarbon or amide compounds; the oxidant is m-chloroperoxybenzoic acid and K2S2O4Or bistrifluoroacetyliodobenzene;
r in formula (II) or formula (III)1、R2、R3Each as defined above.
Further, the solvent is preferably chlorobenzene, 1, 2-dichlorobenzene, 1,2, 4-trichlorobenzene or DMF.
Further, the volume of the solvent is 4-8 mL/mmol based on the amount of the triazine compound represented by formula (II).
In the preparation method of the invention, the post-treatment of the reaction solution can adopt the following method: after the reaction is finished, adding a sodium thiosulfate aqueous solution with the mass fraction of 10% into the obtained reaction liquid, extracting with dichloromethane, combining organic layers, drying with anhydrous sodium sulfate, concentrating, performing column chromatography separation by using dichloromethane and ethyl acetate as eluent in the volume ratio of 25:1, collecting eluent containing the target compound, performing reduced pressure evaporation to remove the solvent, and drying to obtain the 1, 2-diketone compound shown in the formula (I); the volume of the aqueous sodium thiosulfate solution is 60mL/mmol based on the amount of the triazine compound represented by the formula (II).
The invention also provides application of the 1, 2-diketone compound in preparing an antitumor medicament.
Furthermore, the tumor is human liver cancer cell (HEPG2) or human breast cancer cell (T47D).
Furthermore, when the tumor is human liver cancer cell (HEPG2), the compound (I-12) or (I-16) has better anti-tumor activity, and the compound (I-1), (I-3), (I-7), (I-8) or (I-14) has certain anti-tumor activity; when the tumor is a human breast cancer cell (T47D), the compounds (I-7), (I-8) or (I-16) have better anti-tumor activity, and the compounds (I-1), (I-2), (I-3) or (I-12) have certain anti-tumor activity.
Compared with the prior art, the invention has the beneficial effects that:
the invention develops the aryl substituted imidazole compound with novel structure and the preparation method thereof, and the process has mild reaction conditions, convenient operation, low cost, high product purity of more than 97 percent and wide industrial application prospect. The aryl-substituted imidazole compound provided by the invention shows a certain antitumor activity, lays a foundation for screening and developing new drugs, and has a good practical value.
(IV) detailed description of the preferred embodiments
The invention will now be further illustrated by the following examples, without limiting the scope of the invention thereto. The raw material formula (II) compound used by the invention is prepared by reacting ester and biguanide under the action of sodium methoxide at room temperature; specific synthetic methods are described in the literature (Bioorganic & Medicinal Chemistry Letters,19(2009), 5644-.
Example 1: preparation of Compound (I-1)
Adding 2-amino-4-dimethylamino-1, 3, 5-triazine (69.9mg, 0.5mmol), acetophenone (162.7mg, 1.4mmol), iodine (254.4mg, 1.0mmol), cuprous chloride (9.6mg,0.1mmol), m-chloroperoxybenzoic acid (132.0mg,0.6mmol) into a reaction vessel, mixing in 1,2, 4-trichlorobenzene (4mL), and stirring in an oil bath at 150 ℃ under an oxygen environment for reaction for 8 hours; after completion of the reaction, 30mL of a 10% aqueous solution of sodium thiosulfate was added, and the mixture was extracted with dichloromethane (30mL × 3), and the organic layers were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and column chromatography was performed (dichloromethane: ethyl acetate ═ 25:1, v: v), distillation under reduced pressure, and drying were performed to obtain the objective compound (I-1) in a yield of 144.5mg, and the yield was 78%.
1H NMR(500MHz,CDCl3)δ10.02(s,1H),7.76(d,J＝7.7Hz,2H),7.58(t,J＝7.7Hz,1H),7.41(t,J＝7.7Hz,2H),7.35(d,J＝7.7Hz,2H),7.28(t,J＝7.7Hz,1H),7.10(t,J＝7.7Hz,2H),3.40(s,3H),3.34(s,3H)
Example 2:
the procedure of example 1 was otherwise identical except for changing 1,2, 4-trichlorobenzene to o-dichlorobenzene (2mL), resulting in a yield of 61.5mg and a yield of 33%.
Example 3:
the procedure of example 1 was otherwise the same except that 1,2, 4-trichlorobenzene was changed to N, N-dimethylformamide, thereby giving a yield of 34.6mg and an yield of 18%. .
Example 4:
the procedure of example 1 was otherwise the same except that 1,2, 4-trichlorobenzene was changed to chlorobenzene at a temperature of 80 ℃ to give a yield of 14.0mg and a yield of 8%.
Example 5:
the m-chloroperoxybenzoic acid was changed to bistrifluoroacetyliodobenzene (PIFA) (245.6mg, 0.6mmol), and the other operations were the same as in example 1, yielding 26.9mg and 15% yield.
Example 6:
changing m-chloroperoxybenzoic acid to potassium persulfate (K)2S2O8) (152.3mg, 0.6mmol), the same procedures as in example 1 were repeated except that the yield was 42.9mg, which was found to be 23%.
Example 7:
the operation was carried out in the same manner as in example 1 except for changing the amount of m-chloroperoxybenzoic acid to (175.9mg, 0.7mmol), thereby obtaining a yield of 126.8mg and a yield of 68%.
Example 8:
the same procedure as in example 1 was carried out except that m-chloroperoxybenzoic acid was not added, whereby the yield was 53.6mg and 28% was obtained.
Example 9:
the amount of iodine was changed to (381.5mg, 1.5mmol), and the other operations were performed as in example 1, yielding 120.6mg in 64% yield.
Example 10:
the procedure of example 1 was otherwise identical, except that iodine was not added, and that yield was 65.0mg and 34%.
Example 11:
the same procedure as in example 1 was carried out without adding cuprous chloride, yielding 98.5mg and 52% yield.
Example 12:
cuprous chloride was changed to cuprous bromide (14.4mg, 0.1mmol) and the other operations were the same as in example 1, yielding 114.2mg and 61% yield.
Example 13:
the procedure of example 1 was otherwise identical except that cuprous chloride was changed to cupric chloride (13.4mg, 0.1mmol), yielding 99.8mg and 53% yield.
Example 14:
the procedure of example 1 was otherwise identical except that cuprous chloride was changed to cupric bromide (22.5mg, 0.1mmol), yielding 131.7mg and 71% yield.
Example 15:
the procedure of example 1 was otherwise identical except that cuprous chloride was changed to cupric acetate (20.8mg, 0.1mmol), yielding 120.0mg and 65% yield.
Example 16:
the reaction time was shortened to 5 hours, and the other operations were carried out in the same manner as in example 1 to obtain a yield of 106.3mg and a yield of 57%.
Example 17:
the amount of acetophenone was changed to (180.8mg, 1.5mmol), and the other operations were performed as in example 1 to yield 116.2mg in 63% yield.
Example 18:
the amount of acetophenone was changed to (144.6mg, 1.2mmol), and the other operations were performed as in example 1 to yield 98.5mg and 53% yield.
Example 19: preparation of Compound (I-2)
The operation was as in example 1 except that acetophenone was changed to p-methoxyacetophenone (216.7mg,1.4mmol), yield was 53.9mg, yield was 25%.
1H NMR(500MHz,CDCl3)δ10.01(s,1H),7.79(d,J＝8.9Hz,2H),7.35(d,J＝8.7Hz,2H),6.90(d,J＝8.9Hz,2H),6.64(d,J＝8.7Hz,2H),3.89(s,3H),3.76(s,3H),3.38(s,3H),3.33(s,3H)
Example 20: preparation of Compound (I-3)
The operation was carried out as in example 7 except that acetophenone was changed to p-methylacetophenone (180.9mg,1.4mmol), and the reaction was carried out for 20 hours to give a yield of 129.8mg in 65% yield.
1H NMR(500MHz,CDCl3)δ10.03(s,1H),7.71(d,J＝8.1Hz,2H),7.29(d,J＝8.1Hz,2H),7.24(d,J＝8.0Hz,2H),6.92(d,J＝8.0Hz,2H),3.40(s,3H),3.34(s,3H),2.45(s,3H),2.29(s,3H)
Example 21: preparation of Compound (I-4)
The operation was as in example 1 except that acetophenone was replaced by p-chloroacetophenone (208.6mg,1.4mmol), yield 200.0mg, yield 90%.
1H NMR(500MHz,CDCl3)δ9.99(s,1H),7.74(d,J＝8.5Hz,2H),7.44(d,J＝8.5Hz,2H),7.29(d,J＝8.4Hz,2H),7.13(d,J＝8.4Hz,2H),3.41(s,3H),3.35(s,3H)
Example 22: preparation of Compound (I-5)
The operation was as in example 1 except that acetophenone was replaced with p-bromoacetophenone (270.3mg,1.4mmol) and m-chloroperoxybenzoic acid (173.3mg,0.8mmol), yielding 219.5mg in 80% yield.
1H NMR(500MHz,CDCl3)δ9.97(s,1H),7.65(d,J＝8.6Hz,2H),7.60(d,J＝8.6Hz,2H),7.29(d,J＝8.4Hz,2H),7.21(d,J＝8.4Hz,2H),3.40(s,3H),3.34(s,3H)
Example 23: preparation of Compound (I-6)
The operation is as in example 1, except that acetophenone is replaced by p-fluoroacetophenone (186.7mg,1.4mmol), yield 127.0mg, 63%.
1H NMR(500MHz,CDCl3)δ9.99(s,1H),7.81(dd,J＝8.6,5.4Hz,2H),7.34(dd,J＝8.6,5.4Hz,2H),7.12(t,J＝8.6Hz,2H),6.84(t,J＝8.6Hz,2H),3.40(s,3H),3.34(s,3H)
Example 24: preparation of Compound (I-7)
The operation was as in example 1 except that acetophenone was changed to m-chloroacetophenone (215.7mg,1.4mmol), m-chloroperoxybenzoic acid (175.1mg,0.8mmol), and the yield was 161.7mg, 74%.
1H NMR(500MHz,CDCl3)δ9.98(s,1H),7.78–7.74(m,1H),7.70(d,J＝7.9Hz,1H),7.59(dd,J＝7.9,1.1Hz,1H),7.42(t,J＝7.9Hz,1H),7.33–7.29(m,2H),7.27–7.24(m,1H),7.15(t,J＝7.8Hz,1H),3.41(s,3H),3.35(s,3H)
Example 25: preparation of Compound (I-8)
The procedure is as in example 1 except that acetophenone is replaced by m-bromoacetophenone (270.9mg,1.4mmol), yielding 161.4mg in 61% yield.
1H NMR(500MHz,CDCl3)δ9.97(s,1H),7.91(t,J＝1.7Hz,1H),7.77–7.71(m,2H),7.49–7.44(m,1H),7.41–7.36(m,2H),7.36–7.33(m,1H),7.10(t,J＝7.8Hz,1H),3.41(s,3H),3.34(s,3H)
Example 26: preparation of Compound (I-9)
The operation was carried out as in example 1 except that acetophenone was changed to m-methoxyacetophenone (218.2mg,1.5mmol), yield was 131.8mg, yield was 61%.
1H NMR(500MHz,CDCl3)δ10.01(s,1H),7.40(d,J＝7.5Hz,1H),7.33(t,J＝7.8Hz,1H),7.23–7.19(m,1H),7.15–7.11(m,1H),6.99(t,J＝7.8Hz,1H),6.94–6.86(m,2H),6.86–6.81(m,1H),3.80(s,3H),3.57(s,3H),3.40(s,3H),3.34(s,3H)
Example 27: preparation of Compound (I-10)
The operation was as in example 1 except that acetophenone was replaced with o-chloroacetophenone (218.7mg,1.4mmol), yield 117.7mg, yield 53%.
1H NMR(500MHz,CDCl3)δ9.98(s,1H),7.58(dd,J＝7.8,1.6Hz,1H),7.44(td,J＝7.8,1.6Hz,1H),7.37–7.34(m,1H),7.30(dd,J＝7.6,1.4Hz,1H),7.26–7.23(m,2H),7.23–7.21(m,1H),7.07(td,J＝7.6,1.4Hz,1H),3.40(s,3H),3.34(s,3H)
Example 28: preparation of Compound (I-11)
The procedure is as in example 7 except that acetophenone is replaced by o-bromoacetophenone (278.6mg,1.4mmol) and the reaction is carried out for 9 hours to give 169.7mg yield of 64%.
1H NMR(500MHz,CDCl3)δ9.99(s,1H),7.61–7.54(m,2H),7.48–7.43(m,1H),7.35(td,J＝7.6,1.8Hz,1H),7.32-7.28(m,2H),7.17–7.13(m,2H),3.40(s,3H),3.35(s,3H)
Example 29: preparation of Compound (I-12)
The operation was as in example 1 except that acetophenone was changed to 2-acetylthiophene (180.4mg,1.4mmol), m-chloroperoxybenzoic acid (176.0mg,0.8mmol), and the yield was 110.4mg, 58%.
1H NMR(500MHz,CDCl3)δ9.91(s,1H),7.82–7.80(m,1H),7.79–7.75(m,1H),7.44(d,J＝4.8Hz,1H),7.20(d,J＝4.3Hz,1H),7.17(t,J＝4.3Hz,1H),6.89(t,J＝4.8Hz,1H),3.39(s,3H),3.34(s,3H)
Example 30: preparation of Compound (I-13)
The operation is as in example 1, except that acetophenone is replaced by 2-acetylfuran (160.0mg,1.5mmol), yield 46.8mg, 26%.
1H NMR(500MHz,CDCl3)δ9.90(s,1H),7.76-7.73(m,1H),7.39(d,J＝3.4Hz,1H),7.26(d,J＝3.4Hz,1H),7.19-7.16(m,1H),6.65(dd,J＝3.6,1.6Hz,1H),6.49(dd,J＝3.6,1.6Hz,1H),3.38(s,3H),3.33(s,3H)
Example 31: preparation of Compound (I-14)
The operation was carried out as in example 1 except that 2-amino-4-dimethylamino-1, 3, 5-triazine was changed to 2-amino-4-diethylamino-1, 3, 5-triazine (84.6mg,0.5mmol), and the yield was 161.0mg and 80%.
1H NMR(500MHz,CDCl3)δ10.03(s,1H),7.75(dd,J＝8.2,1.1Hz,2H),7.60–7.55(m,1H),7.40(t,J＝7.8Hz,2H),7.37–7.34(m,2H),7.30–7.28(m,1H),7.10(t,J＝7.8Hz,2H),3.80(q,J＝7.1Hz,2H),3.77(q,J＝7.1Hz,2H),1.30(t,J＝7.1Hz,3H),1.29(t,J＝7.1Hz,3H)
Example 32: preparation of Compound (I-15)
The operation was carried out in the same manner as in example 1 except that 2-amino-4-dimethylamino-1, 3, 5-triazine was replaced with 2-amino-4-morpholinyl-1, 3, 5-triazine (84.6mg,0.5mmol), whereby the yield was 99.6mg and 48%.
1H NMR(500MHz,CDCl3)δ10.04(s,1H),7.78–7.74(m,2H),7.61–7.57(m,1H),7.44–7.40(m,2H),7.37–7.33(m,2H),7.32–7.28(m,1H),7.13–7.09(m,2H),4.09–4.02(m,4H),3.84–3.80(m,4H)
Example 33: preparation of Compound (I-16)
The operation was carried out as in example 1 except that 2-amino-4-dimethylamino-1, 3, 5-triazine was changed to 2-amino-4-pyrrolidinyl-1, 3, 5-triazine (83.0mg,0.5mmol), whereby the yield was 132.3mg and 66%.
1H NMR(500MHz,CDCl3)δ10.04(s,1H),7.77(d,J＝7.4Hz,2H),7.58(t,J＝7.4Hz,1H),7.41(t,J＝7.4Hz,2H),7.36(d,J＝7.6Hz,2H),7.28(t.,J＝7.6Hz,1H),7.10(t,J＝7.6Hz,2H),3.79(t,J＝6.6Hz,2H),3.75(t,J＝6.6Hz,2H),2.10–2.05(m,4H)
Example 34: preparation of Compound (I-17)
The operation is as in example 1, except that 2-amino-4-dimethylamino-1, 3, 5-triazine is replaced with 2-amino-4-piperidinyl-1, 3, 5-triazine (90.2mg,0.5mmol), giving a yield of 146.4mg, 71%.
1H NMR(500MHz,CDCl3)δ10.00(s,1H),7.75(d,J＝7.4Hz,2H),7.58(t,J＝7.4Hz,1H),7.41(t,J＝7.4Hz,2H),7.35(d,J＝6.8Hz,2H),7.29(t,J＝6.8Hz,1H),7.11(t,J＝6.8Hz,2H),4.04-3.95(m,4H),1.78-1.66(m,6H)
Example 35: in vitro anti-human liver cancer cell (HEPG2) or human breast cancer cell (T47D) activity test method for biological activity of anti-human liver cancer cell (HEPG2) or human breast cancer cell (T47D): MTT method
The experimental steps are as follows:
1) preparation of samples: for soluble samples, each 1mg was dissolved in 20. mu.L DMSO, 2. mu.L was diluted with 1000. mu.L of culture medium to a concentration of 100. mu.g/mL, and then the culture medium was serially diluted to the use concentration.
2) Culture of cells
2.1) preparation of culture medium, wherein each 1000mL of culture medium contains 80 ten thousand units of penicillin, 1.0g of streptomycin and 10% of inactivated fetal calf serum.
2.2) culture of cells: inoculating tumor cells into culture medium, standing at 37 deg.C and 5% CO2Culturing in an incubator, and carrying out passage for 3-5 days.
3) Determination of the inhibition of tumor cell growth by samples
The cells were digested with EDTA-pancreatin digest and diluted to 1X 10 with medium5Perml, 100 uL/well in 96-well cell culture plates, 37 ℃ 5% CO2Culturing in an incubator. After 24h of inoculation, samples diluted with medium were added, 100. mu.L per well, 3 wells per concentration, and placed at 37 ℃ in 5% CO2Culturing in incubator, adding 5mg/mL MTT into cell culture well after 72 hr, adding 10 μ L MTT per well, incubating at 37 deg.C for 4 hr, addingDMSO, 150 μ L per well, shaken with a shaker to completely solubilize the formazan, which is colorimetric with a microplate reader at a wavelength of 570 nm. The inhibition rate of the sample on the tumor cells was calculated by using cells cultured in the medium containing no sample and the same concentration of DMSO as a control under the same conditions, and the results are shown in Table 1. The inhibition effect of 8 samples of the compounds (I-1), (I-2), (I-3), (I-7), (I-8), (I-12), (I-14) and (I-16) on the growth of liver cancer cells or human breast cancer cells in vitro was determined by taking human liver cancer cells (HEPG2) or human breast cancer cells (T47D) as models (the results are detailed in Table 1).
TABLE 1.60 μmol/L inhibition ratio of each compound to human hepatoma cells (HepG2) or human breast cancer cells (T47D)%
Compound (IV) was prepared according to literature procedures (org. biomol. chem.,2017,15, 5564-5570).
Claims (10)
1. 1, 2-diketones of formula (I):
in the formula (I), R1Or R2Each independently is C1～C10Alkyl, or R1、R2Are connected into a ring and are combined with N between the two to form C containing N or N, O4～C8The heterocyclic ring of (1); r3Is C4～C8Heteroaryl, phenyl or by C1～C10Alkyl radical, C1～C10Alkoxy or halogen substituted phenyl.
2. The 1, 2-diketones according to formula (I) according to claim 1 or 2, characterized in that the 1, 2-diketones according to formula (I) are one of the following:
3. a process for the preparation of 1, 2-diketones of formula (I) according to claim 1, characterized in that it comprises:
mixing a triazine compound shown in a formula (II) and a ketone compound shown in a formula (III), adding the mixture into a solvent, stirring and reacting for 5-20 hours at the temperature of 80-150 ℃ under an oxygen atmosphere, and after the reaction is finished, obtaining a reaction liquid and carrying out post-treatment to obtain a 1, 2-diketone compound shown in a formula (I); the mass ratio of the triazine compound shown in the formula (II) to the ketone compound shown in the formula (III) is 1: 2.4 to 3.0; the solvent is halogenated aromatic hydrocarbon or amide compounds;
wherein R is1Or R2Each independently is C1～C10Alkyl, or R1、R2Are connected into a ring and are combined with N between the two to form C containing N or N, O4～C8The heterocyclic ring of (1); r3Is C4～C8Heteroaryl, phenyl or by C1～C10Alkyl radical, C1～C10Alkoxy or halogen substituted phenyl.
4. A process for the preparation of 1, 2-diketones of formula (I) according to claim 3, characterized in that: before the reaction, copper salt is added into the solvent, and the mass ratio of the triazine compound shown in the formula (II) to the copper salt is 1: 0 to 0.2, and the amount of the copper salt is not 0.
5. A process for the preparation of 1, 2-diketones of formula (I) according to claim 3, characterized in that: before the reaction, halogen is also added into the solvent, and the mass ratio of the triazine compound shown in the formula (II) to the halogen is 1: 0 to 3.0, and the amount of the halogen is not 0.
6. A process for the preparation of 1, 2-diketones of formula (I) according to claim 3, characterized in that: before the reaction, an oxidant is added into the solvent, and the quantity ratio of the triazine compound shown in the formula (II) to the halogen is 1: 0 to 1.4, wherein the amount of the oxidant is not 0; the oxidant is m-chloroperoxybenzoic acid and K2S2O4Or bis-trifluoroacetyliodobenzene.
7. A process for the preparation of 1, 2-diketones of formula (I) according to claim 3, characterized in that: the solvent is chlorobenzene, 1, 2-dichlorobenzene, 1,2, 4-trichlorobenzene or DMF; the volume of the solvent is 4-8 mL/mmol based on the amount of the triazine compound represented by the formula (II).
8. The process for producing 1, 2-diketones of the formula (I) according to claim 3, wherein the post-treatment of the reaction solution is: after the reaction is finished, adding a sodium thiosulfate aqueous solution with the mass fraction of 10% into the obtained reaction liquid, extracting with dichloromethane, combining organic layers, drying with anhydrous sodium sulfate, concentrating, performing column chromatography separation by using dichloromethane and ethyl acetate as eluent in the volume ratio of 25:1, collecting eluent containing the target compound, performing reduced pressure evaporation to remove the solvent, and drying to obtain the 1, 2-diketone compound shown in the formula (I); the volume of the aqueous sodium thiosulfate solution is 60mL/mmol based on the amount of the triazine compound represented by the formula (II).
9. The use of a 1, 2-dione compound of formula (I) according to claim 1 in the preparation of an anti-tumor medicament.
10. The use of claim 9, wherein the tumor is a human liver cancer cell or a human breast cancer cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806332.9A CN113603694B (en) | 2021-07-16 | 2021-07-16 | 1, 2-diketone compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110806332.9A CN113603694B (en) | 2021-07-16 | 2021-07-16 | 1, 2-diketone compound and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113603694A true CN113603694A (en) | 2021-11-05 |
| CN113603694B CN113603694B (en) | 2022-07-22 |
Family
ID=78337712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110806332.9A Active CN113603694B (en) | 2021-07-16 | 2021-07-16 | 1, 2-diketone compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113603694B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115974879A (en) * | 2022-12-16 | 2023-04-18 | 浙江工业大学 | Preparation method of polysubstituted imidazo heterocyclic compound |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1568324A (en) * | 2001-09-13 | 2005-01-19 | Sbr制药公司 | 1-glyoxylamide indolizines for treating cancer |
| WO2005099824A1 (en) * | 2004-03-30 | 2005-10-27 | Synta Pharmaceuticals, Corp. | 1-glyoxylamide indolizines for treating lung and ovarian cancer |
| CN101090720A (en) * | 2004-11-08 | 2007-12-19 | 巴克斯特国际公司 | Nanoparticulate compositions of tubulin inhibitor compounds |
| WO2010139982A1 (en) * | 2009-06-02 | 2010-12-09 | The University Of Sheffield | Indole derivatives for the stimulation of stem cell proliferation |
-
2021
- 2021-07-16 CN CN202110806332.9A patent/CN113603694B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1568324A (en) * | 2001-09-13 | 2005-01-19 | Sbr制药公司 | 1-glyoxylamide indolizines for treating cancer |
| WO2005099824A1 (en) * | 2004-03-30 | 2005-10-27 | Synta Pharmaceuticals, Corp. | 1-glyoxylamide indolizines for treating lung and ovarian cancer |
| CN101090720A (en) * | 2004-11-08 | 2007-12-19 | 巴克斯特国际公司 | Nanoparticulate compositions of tubulin inhibitor compounds |
| WO2010139982A1 (en) * | 2009-06-02 | 2010-12-09 | The University Of Sheffield | Indole derivatives for the stimulation of stem cell proliferation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115974879A (en) * | 2022-12-16 | 2023-04-18 | 浙江工业大学 | Preparation method of polysubstituted imidazo heterocyclic compound |
| CN115974879B (en) * | 2022-12-16 | 2024-03-26 | 浙江工业大学 | Preparation method of polysubstituted imidazo heterocyclic compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113603694B (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110183378B (en) | Nicotinamide derivative and catalytic synthesis method thereof | |
| CN109232363B (en) | Synthetic method of 3-selenocyanoindole compound | |
| CN113603694B (en) | 1, 2-diketone compound and preparation method and application thereof | |
| CN106632043A (en) | Licochalcone A pyrazoline derivatives with antitumor activity and synthesis method thereof | |
| CN110156659B (en) | Preparation method of polyfluoro-substituted 3-hydroxyl oxindole compound | |
| CN109956894B (en) | Synthetic method of 3, 3' -disubstituted-2-indolone compound | |
| CN109651333A (en) | A kind of 2- indol-3-yl-quinolines with anti-tumor activity and its preparation method and application | |
| CN113444095B (en) | Triazine substituted imidazole compound and preparation method and application thereof | |
| CN110511214B (en) | Diamine substituted aromatic heterocyclic compound and preparation method and application thereof | |
| CN115974879B (en) | Preparation method of polysubstituted imidazo heterocyclic compound | |
| CN107880029A (en) | Design, synthesis and the application of a kind of indole derivatives antitumoral compounds containing pyrazol framework | |
| CN112824408A (en) | Propenone derivative of moxifloxacin and preparation method and application thereof | |
| CN112250639B (en) | Heterocyclic substituted arylamine compound and preparation method and application thereof | |
| CN115745902A (en) | Preparation method of N-triazine amide compound | |
| CN111138445B (en) | Method for preparing 5, 12-dioxaanthracene-6, 11-diketone compound by nickel catalysis | |
| CN115819363A (en) | Ketone amide compound and preparation method and application thereof | |
| CN108409630A (en) | The preparation method of 3- hydroxyl -2- indolone derivatives in a kind of water phase | |
| CN111943939B (en) | Synthesis method of chromanone compound and agricultural biological activity thereof | |
| CN114213396B (en) | Indole-2-ketone compound and preparation method and application thereof | |
| CN113292573B (en) | Indolizine chromogen ketone compound with anti-tumor activity and preparation method and application thereof | |
| CN115785142B (en) | Carbazole aryne precursor compound and preparation method and application thereof | |
| CN109467558B (en) | 1-hydropyrrolizine derivative and synthesis method and application thereof | |
| CN114989121B (en) | Preparation method and application of 3,4, 6-trisubstituted pyrone | |
| CN108558895B (en) | Isatin mother nucleus peroxide compound with antibacterial activity and preparation method thereof | |
| CN117466915A (en) | Chromone-containing benzo [ d ] imidazo [2,1-b ] thiazole compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |